Pharming Group Reports Mixed Q1 2026 Results Amid Joenja Growth and RUCONEST Decline
Event summary
- Q1 2026 total revenues were US$72.4 million, an 8% decrease compared to Q1 2025.
- RUCONEST® revenue declined 15% to US$58.4 million due to inventory drawdowns and market exit.
- Joenja® revenue increased 34% to US$14.1 million, driven by strong U.S. and international momentum.
- Positive net cash flow from operations of US$2.0 million in the quarter.
- Joenja® approved in Japan and received positive CHMP opinion for APDS in Europe.
The big picture
Pharming Group's Q1 2026 results highlight a strategic pivot, with Joenja® emerging as a key growth driver while RUCONEST® faces revenue challenges due to market exits and inventory adjustments. The company's focus on regulatory progress and pipeline development positions it for long-term growth in the rare disease market. The ability to manage cash flow and sustain Joenja®'s momentum will be critical in the coming quarters.
What we're watching
- Regulatory Progress
- The pace at which Pharming secures pediatric label expansion for Joenja® in the U.S. and final approval in Europe will impact its growth trajectory.
- Market Dynamics
- Whether Joenja® can sustain its strong revenue growth amid competitive market dynamics and inventory fluctuations.
- Pipeline Development
- The potential of leniolisib in broader primary immunodeficiencies and the progress of napazimone (KL1333) in mitochondrial diseases.
Related topics